# Eli Lilly & Company – FDA 483 Response, Mar 16, 2021

Source: https://www.keypedia.com/records/483_response/eli-lilly-company/48bca0f9-fb52-4f51-9e65-4d0fd6283a21

> FDA 483_RESPONSE for Eli Lilly & Company on March 16, 2021. Product: Drugs. Access full analysis and detailed observations.

---

## Details

- Record Type: 483_RESPONSE
- Company Name: Eli Lilly & Company
- Inspection Date: 2021-03-16
- Product Type: Drugs
- Office Name: Division of Pharmaceutical Quality Operations I

## Related Documents

- [483 - 2025-05-20](https://www.keypedia.com/records/483/eli-lilly-company/885fecd9-f6cd-48fd-90eb-66d12ec35d07) — date: May 20, 2025
- [483 - 2023-10-06](https://www.keypedia.com/records/483/eli-lilly-company/f0349542-8a47-4147-9164-7ecacf1fcd4e) — date: October 6, 2023
- [483 - 2023-09-15](https://www.keypedia.com/records/483/eli-lilly-company/49ac02bf-312b-43ae-96e2-4cf015602e85) — date: September 15, 2023
- [483 - 2023-06-16](https://www.keypedia.com/records/483/eli-lilly-company/ad3d5c22-c165-4f63-91cc-163c31217be2) — date: June 16, 2023
- [EIR - 2023-05-18](https://www.keypedia.com/records/eir/eli-lilly-company/15f9ed35-a475-4557-b1f2-753ea60f17a2) — date: May 18, 2023

## Related Officers

- [Director of Compliance](https://www.keypedia.com/people/nicholas-f-lyons/e52983af-3992-493c-addd-ff1dfa59eefb)
- [Program Division Director](https://www.keypedia.com/people/art-o-czabaniuk/37f1e249-9ee6-4275-9c28-391d93659b85)
- [Ainhoa Nieto](https://www.keypedia.com/people/ainhoa-nieto/89b22b5d-c0a2-4f0f-9c2c-8244b5cbb793)
- [Ms.](https://www.keypedia.com/people/ann-connery/49b086d7-8b1c-4399-9666-b7d96b340e71)
- [Consumer Safety Officer](https://www.keypedia.com/people/kenneth-o-gee/d61312c0-1422-4487-a5d6-ec6e76d242ee)

Company: https://www.keypedia.com/companies/eli-lilly-company/fc56eed7-d261-4de3-865e-c2aa54162adf

Office: https://www.keypedia.com/offices/division-of-pharmaceutical-quality-operations-i/6ded4818-ee3a-46a1-84c1-36de58502b02